Viorel Jinga - Academia.edu (original) (raw)

Papers by Viorel Jinga

International Journal of Molecular Sciences

Renal cell carcinoma (RCC) represents 85–95% of kidney cancers and is the most frequent type of r... more Renal cell carcinoma (RCC) represents 85–95% of kidney cancers and is the most frequent type of renal cancer in adult patients. It accounts for 3% of all cancer cases and is in 7th place among the most frequent histological types of cancer. Clear cell renal cell carcinoma (ccRCC), accounts for 75% of RCCs and has the most kidney cancer-related deaths. One-third of the patients with ccRCC develop metastases. Renal cancer presents cellular alterations in sugars, lipids, amino acids, and nucleic acid metabolism. RCC is characterized by several metabolic dysregulations including oxygen sensing (VHL/HIF pathway), glucose transporters (GLUT 1 and GLUT 4) energy sensing, and energy nutrient sensing cascade. Metabolic reprogramming represents an important characteristic of the cancer cells to survive in nutrient and oxygen-deprived environments, to proliferate and metastasize in different body sites. The phosphoinositide 3-kinase-AKT-mammalian target of the rapamycin (PI3K/AKT/mTOR) signali...

Despite being closely monitored for their current and more acute pathology, cancer screening and ... more Despite being closely monitored for their current and more acute pathology, cancer screening and in particular uro-logical cancer screening is often neglected in patients with end stage renal disease undergoing dialysis. This review encompasses the diagnosis of urological malignancies that occur in end-stage renal patients after the initiation of hemodialysis. We conducted a literature search in PubMed and UpToDate databases using the diagnostic criteria for urological malignancies in hemodialysis patients. Based on the existing data in the current literature it seems that patients undergoing dialysis have a higher risk of developing cancer than the general population, with peculiarities in both cancer detection and investigation that need to be addressed. Further studies should be made in order to improve cancer screening and diagnosis in dialysis patients. Rezumat Deși pacienţii aflaţi în program de dializă sunt atent monitorizaţi pentru patologia lor prezentă și de obicei acută, ...

Clinical Cancer Research, 2018

Purpose: PI3K–Akt–mTOR and androgen receptor (AR) signaling are commonly aberrantly activated in ... more Purpose: PI3K–Akt–mTOR and androgen receptor (AR) signaling are commonly aberrantly activated in metastatic castration-resistant prostate cancer (mCRPC), with PTEN loss associating with poor prognosis. We therefore conducted a phase Ib/II study of the combination of ipatasertib, an Akt inhibitor, with the CYP17 inhibitor abiraterone in patients with mCRPC. Patients and Methods: Patients were randomized 1:1:1 to ipatasertib 400 mg, ipatasertib 200 mg, or placebo, with abiraterone 1,000 mg orally. Coprimary efficacy endpoints were radiographic progression-free survival (rPFS) in the intent-to-treat population and in patients with PTEN-loss tumors. Results: rPFS was prolonged in the ipatasertib cohort versus placebo, with similar trends in overall survival and time-to-PSA progression. A larger rPFS prolongation for the combination was demonstrated in PTEN-loss tumors versus those without. The combination was well tolerated, with no treatment-related deaths. Conclusions: In mCRPC, combi...

ROMANIAN BIOTECHNOLOGICAL LETTERS, 2019

In our study, we investigated the utility of genome-wide association study results in defining a ... more In our study, we investigated the utility of genome-wide association study results in defining a risk score based on prostate cancer risk variants in the Romanian population. The study population consisted of 1301 unrelated histopathologically confirmed prostate cancer (PCa) cases and 1,073 male controls consisting of patients admitted for urological and surgical conditions, excluding cancer. None of the tested variants in the Romanian GWAS reached a genome-wide significance (p-value lower than 5x10-8), but 36 markers reached p-values of 1x10-7. 17 of the previously-reported SNPs replicated in the Romanian cohort. Evaluating the total risk observed in the general PCa GWAS compared with the GWAS performed in the Gleason Score <7 subcohorts, we found a 5.1 times difference in-between the two predicted risk scores in individuals carrying all 17 variants.

Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie, 2007

Primary pure small cell carcinoma of the urinary bladder is an extremely rare and highly aggressi... more Primary pure small cell carcinoma of the urinary bladder is an extremely rare and highly aggressive tumor with an average five-year survival rate of less than 10% as cited by multiple case reports. It accounts for about 0.5-1% of all bladder tumors. We present the case of a 44-years-old man, smoker (10 cigarettes/day) hospitalized in the Department of Urology, from the "Prof. dr. Th. Burghele" Hospital, Bucharest, for one month intermittent hematuria. Ultrasonography showed a sessile tumoral mass, sized 37/30mm. Transurethral resection of the tumor mass was performed and tissue fragments were sent to the pathologic lab to establish the histologic type, the degree of differentiation and invasion. Fragments of the tumor were fixed in 10% formaldehyde, paraffin embedded and processed as standard technique; the sections were stained with HE, VG and immunohistochemically with: CROMO, EMA, NSE, CD56, NK1, p53 and betaHCG. The microscopic examination reveled a tumor proliferation...

International Journal of Molecular Sciences

Renal cell carcinoma (RCC) represents 85–95% of kidney cancers and is the most frequent type of r... more Renal cell carcinoma (RCC) represents 85–95% of kidney cancers and is the most frequent type of renal cancer in adult patients. It accounts for 3% of all cancer cases and is in 7th place among the most frequent histological types of cancer. Clear cell renal cell carcinoma (ccRCC), accounts for 75% of RCCs and has the most kidney cancer-related deaths. One-third of the patients with ccRCC develop metastases. Renal cancer presents cellular alterations in sugars, lipids, amino acids, and nucleic acid metabolism. RCC is characterized by several metabolic dysregulations including oxygen sensing (VHL/HIF pathway), glucose transporters (GLUT 1 and GLUT 4) energy sensing, and energy nutrient sensing cascade. Metabolic reprogramming represents an important characteristic of the cancer cells to survive in nutrient and oxygen-deprived environments, to proliferate and metastasize in different body sites. The phosphoinositide 3-kinase-AKT-mammalian target of the rapamycin (PI3K/AKT/mTOR) signali...

Despite being closely monitored for their current and more acute pathology, cancer screening and ... more Despite being closely monitored for their current and more acute pathology, cancer screening and in particular uro-logical cancer screening is often neglected in patients with end stage renal disease undergoing dialysis. This review encompasses the diagnosis of urological malignancies that occur in end-stage renal patients after the initiation of hemodialysis. We conducted a literature search in PubMed and UpToDate databases using the diagnostic criteria for urological malignancies in hemodialysis patients. Based on the existing data in the current literature it seems that patients undergoing dialysis have a higher risk of developing cancer than the general population, with peculiarities in both cancer detection and investigation that need to be addressed. Further studies should be made in order to improve cancer screening and diagnosis in dialysis patients. Rezumat Deși pacienţii aflaţi în program de dializă sunt atent monitorizaţi pentru patologia lor prezentă și de obicei acută, ...

Clinical Cancer Research, 2018

Purpose: PI3K–Akt–mTOR and androgen receptor (AR) signaling are commonly aberrantly activated in ... more Purpose: PI3K–Akt–mTOR and androgen receptor (AR) signaling are commonly aberrantly activated in metastatic castration-resistant prostate cancer (mCRPC), with PTEN loss associating with poor prognosis. We therefore conducted a phase Ib/II study of the combination of ipatasertib, an Akt inhibitor, with the CYP17 inhibitor abiraterone in patients with mCRPC. Patients and Methods: Patients were randomized 1:1:1 to ipatasertib 400 mg, ipatasertib 200 mg, or placebo, with abiraterone 1,000 mg orally. Coprimary efficacy endpoints were radiographic progression-free survival (rPFS) in the intent-to-treat population and in patients with PTEN-loss tumors. Results: rPFS was prolonged in the ipatasertib cohort versus placebo, with similar trends in overall survival and time-to-PSA progression. A larger rPFS prolongation for the combination was demonstrated in PTEN-loss tumors versus those without. The combination was well tolerated, with no treatment-related deaths. Conclusions: In mCRPC, combi...

ROMANIAN BIOTECHNOLOGICAL LETTERS, 2019

In our study, we investigated the utility of genome-wide association study results in defining a ... more In our study, we investigated the utility of genome-wide association study results in defining a risk score based on prostate cancer risk variants in the Romanian population. The study population consisted of 1301 unrelated histopathologically confirmed prostate cancer (PCa) cases and 1,073 male controls consisting of patients admitted for urological and surgical conditions, excluding cancer. None of the tested variants in the Romanian GWAS reached a genome-wide significance (p-value lower than 5x10-8), but 36 markers reached p-values of 1x10-7. 17 of the previously-reported SNPs replicated in the Romanian cohort. Evaluating the total risk observed in the general PCa GWAS compared with the GWAS performed in the Gleason Score <7 subcohorts, we found a 5.1 times difference in-between the two predicted risk scores in individuals carrying all 17 variants.

Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie, 2007

Primary pure small cell carcinoma of the urinary bladder is an extremely rare and highly aggressi... more Primary pure small cell carcinoma of the urinary bladder is an extremely rare and highly aggressive tumor with an average five-year survival rate of less than 10% as cited by multiple case reports. It accounts for about 0.5-1% of all bladder tumors. We present the case of a 44-years-old man, smoker (10 cigarettes/day) hospitalized in the Department of Urology, from the "Prof. dr. Th. Burghele" Hospital, Bucharest, for one month intermittent hematuria. Ultrasonography showed a sessile tumoral mass, sized 37/30mm. Transurethral resection of the tumor mass was performed and tissue fragments were sent to the pathologic lab to establish the histologic type, the degree of differentiation and invasion. Fragments of the tumor were fixed in 10% formaldehyde, paraffin embedded and processed as standard technique; the sections were stained with HE, VG and immunohistochemically with: CROMO, EMA, NSE, CD56, NK1, p53 and betaHCG. The microscopic examination reveled a tumor proliferation...